Advances in immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1) and its ligand programmed cell death ligand-1 (PD-L1) have dramatically changed the treatment landscape for non-small cell lung cancer (NSCLC), providing durable clinical response in a subset of patients[1,2]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.